

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Prevymis (letermovir)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	100 days of treatment*

Medications	Quantity Limit	
Prevymis (letermovir) 240 mg, 480 mg	1 tablet per day	Commercial, MCD
Prevymis (letermovir) 240 mg/12 ml, 480 mg/24 ml	1 vial per day	Commercial, AGP, VA MCD

*Requests for an additional course of Prevymis (letermovir) may be approved in individuals undergoing an additional allogeneic hematopoietic stem cell transplant.

APPROVAL CRITERIA

Requests for oral Prevymis (letermovir) may be approved when the following criteria are met:

- I. Individual is cytomegalovirus (CMV)-seropositive and is using to prevent CMV infection or disease; **AND**
- II. Individual is an allogeneic hematopoietic stem cell transplant recipient; **AND**
- III. Therapy will be initiated between Day 0 and Day 28 post-transplantation.

Requests for injectable Prevymis (letermovir) may be approved when the following criteria are met:

- I. Individual is cytomegalovirus (CMV)-seropositive and is using to prevent CMV infection or disease; **AND**
- II. Individual is an allogeneic hematopoietic stem cell transplant recipient; **AND**
- III. Therapy will be initiated between Day 0 and Day 28 post-transplantation; **AND**
- IV. Individual is unable to use the oral dosage form.

Requests for oral or injectable Prevymis (letermovir) may not be approved for the following:

- I. All other indications not included above; **OR**
- II. Treatment of known CMV disease; **OR**
- III. Individual has severe hepatic impairment (Child-Pugh C).

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: September 5, 2019.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
4. Wingard JR. Prevention of viral infections in hematopoietic cell transplant recipients. Last updated: January 9, 2019. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: September 5, 2019.